Stocks and Investing
Stocks and Investing
Tue, August 13, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gregory Renza Reiterated (SPRB) at Hold and Held Target at $2 on, Aug 13th, 2024
Gregory Renza of RBC Capital, Reiterated "Spruce Biosciences, Inc." (SPRB) at Hold and Held Target at $2 on, Aug 13th, 2024.
Gregory has made no other calls on SPRB in the last 4 months.
There are 2 other peers that have a rating on SPRB. Out of the 2 peers that are also analyzing SPRB, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Hold on, Wednesday, June 5th, 2024
This is the rating of the analyst that currently disagrees with Gregory
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Decreased Target to $3 on, Thursday, June 13th, 2024
Contributing Sources